β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study

Background Individual susceptibility to exacerbations in chronic obstructive pulmonary disease (COPD) is likely influenced by genetic factors; however, most such variance is unexplained. We hypothesised that β2-adrenergic receptor genotypes, Gly16Arg (rs1042713, c.46G>A) and Gln27Glu (rs1042714, c.79C>G) influence risk of severe exacerbations in COPD. Methods Among 96 762 individuals in the Copenhagen General Population Study, we identified 5262 with COPD (forced expiratory volume in one second divided by forced vital capacity, FEV1/FVC, below 0.7, FEV1 less than 80% of predicted value, age above 40 years and no asthma) who had genotyping performed. Severe exacerbations were defined as acute admissions due to COPD during 5 years of follow-up (mean 3.4 years). 923 individuals with COPD diagnosed similarly in the Copenhagen City Heart Study (CCHS) were used for replication analyses. Results We recorded 461 severe exacerbations in 5262 subjects. The HRs for severe exacerbations were 1.62 (95% CI 1.30 to 2.03, p=0.00002) for 16Gly/Arg heterozygotes and 1.41 (1.04 to 1.91, p=0.03) for 16Arg homozygotes, compared with 16Gly homozygotes. HRs were 1.35 (1.03 to 1.76, p=0.03) for 27Gln/Glu heterozygotes and 1.49 (1.12 to 1.98, p=0.006) for 27Gln homozygotes, compared with 27Glu homozygotes. Similar trends were observed in the CCHS. Among 27Gln homozygotes only, HRs were 5.20 (1.81 to 14.9, p=0.002) for 16Gly/Arg heterozygotes and 4.03 (1.40 to 11.6, p=0.01) for 16Arg homozygotes, compared with 16Gly homozygotes. Conclusion Common β2-adrenergic receptor genotypes influence risk of severe exacerbations in COPD, potentially mainly by genetic influence of the 16Arg allele in rs1042713.

[1]  P. Krawczyk,et al.  Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary disease. , 2017, Pulmonary pharmacology & therapeutics.

[2]  E. Toraih,et al.  Beta2-adrenergic receptor gene haplotypes and bronchodilator response in Egyptian patients with chronic obstructive pulmonary disease. , 2017, Advances in medical sciences.

[3]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.

[4]  E. Burchard,et al.  Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment. , 2016, The Journal of allergy and clinical immunology.

[5]  J. Hallas,et al.  Medically treated exacerbations in COPD by GOLD 1-4: A valid, robust, and seemingly low-biased definition. , 2015, Respiratory medicine.

[6]  B. Nordestgaard,et al.  Fibrinogen and α1-antitrypsin in COPD exacerbations , 2015, Thorax.

[7]  J. Soriano,et al.  Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. , 2015, The New England journal of medicine.

[8]  Alvar Agusti,et al.  Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. , 2015, Chest.

[9]  J. Ribeiro,et al.  Asthma: Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors , 2014, Allergy, Asthma & Clinical Immunology.

[10]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[11]  E. Israel,et al.  Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. , 2014, The Lancet. Respiratory medicine.

[12]  J. Hallas,et al.  Characteristics of undertreatment in COPD in the general population. , 2013, Chest.

[13]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[14]  S. Lewitzky,et al.  A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients , 2011, The Pharmacogenomics Journal.

[15]  W. Bailey,et al.  ADRB2 polymorphisms and budesonide/formoterol responses in COPD. , 2012, Chest.

[16]  B. Nordestgaard,et al.  &bgr;2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies , 2011, European Respiratory Journal.

[17]  K. Helweg-larsen The Danish Register of Causes of Death , 2011, Scandinavian journal of public health.

[18]  P. Lange,et al.  Validity and underrecording of diagnosis of COPD in the Danish National Patient Registry. , 2011, Respiratory medicine.

[19]  J. Hallas,et al.  The Danish National Prescription Registry , 2011, Scandinavian journal of public health.

[20]  Mei-Jie Zhang,et al.  Analyzing Competing Risk Data Using the R timereg Package. , 2011, Journal of statistical software.

[21]  E. Silverman,et al.  Genetic influences on Chronic Obstructive Pulmonary Disease - a twin study. , 2010, Respiratory medicine.

[22]  B. Lipworth,et al.  Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. , 2009, The Journal of allergy and clinical immunology.

[23]  A. Gillissen,et al.  Polymorphisms of the ß2 adrenoreceptor gene in chronic obstructive pulmonary disease , 2009, Therapeutic advances in respiratory disease.

[24]  B. Lipworth,et al.  Arginine-16 β2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol , 2006, Thorax.

[25]  Malcolm W Johnson Molecular mechanisms of β2-adrenergic receptor function, response, and regulation , 2006 .

[26]  A. Clark,et al.  The role of haplotypes in candidate gene studies , 2004, Genetic epidemiology.

[27]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[28]  Britton,et al.  β2‐adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  S. Green,et al.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.

[30]  B Järvholm,et al.  Asthma and asthma-like symptoms in adults assessed by questionnaires. A literature review. , 1993, Chest.